PAX2 and neoplasm: The immunohistochemical profile of the current tumor is comparable to previously reported TLFCK cases (AE1/AE3+, CK7+, PAX-2+, PAX-8+, vimentin+, EMA+, TTF-1−, TG−, CD56−, WT-1−, CD10−, and CEA−).